Jpmorgan Chase & CO Xtant Medical Holdings, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Xtant Medical Holdings, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 112 shares of XTNT stock, worth $59. This represents 0.0% of its overall portfolio holdings.
Number of Shares
112
Previous 13,956
99.2%
Holding current value
$59
Previous $16,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding XTNT
# of Institutions
30Shares Held
90.1MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA73.1MShares$38.8 Million1.11% of portfolio
-
Altium Capital Management LP New York, NY7.42MShares$3.93 Million2.49% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT3.58MShares$1.9 Million0.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.15MShares$1.14 Million0.0% of portfolio
-
Juniper Investment Company, LLC New York, NY1.32MShares$699,0400.39% of portfolio
About Xtant Medical Holdings, Inc.
- Ticker XTNT
- Exchange NYSE
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 108,226,000
- Market Cap $57.4M
- Description
- Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healin...